Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 8mg;  ;   - film coated tablet - 8 mg - active: risperidone 8mg     excipient: colloidal silicon dioxide hypromellose indigo carmine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc quinoline yellow sodium laurilsulfate titanium dioxide

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - haloperidol 0.5mg - tablet - 0.5 mg - active: haloperidol 0.5mg excipient: acacia acid green 50 calcium hydrogen phosphate dihydrate lactose monohydrate magnesium stearate maize starch quinoline yellow - the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - carbidopa monohydrate 26.9mg equivalent to carbidopa 25 mg; levodopa 100mg; carbidopa monohydrate 27mg equivalent to carbidopa 25 mg; levodopa 100mg; carbidopa monohydrate 27mg equivalent to carbidopa 25 mg; levodopa 100mg - tablet - 25/100 - active: carbidopa monohydrate 26.9mg equivalent to carbidopa 25 mg levodopa 100mg excipient: crotonic acid-polyvinylacetate copolymer magnesium stearate maize starch microcrystalline cellulose purified water quinoline yellow starch active: carbidopa monohydrate 27mg equivalent to carbidopa 25 mg levodopa 100mg excipient: crospovidone hyprolose magnesium stearate microcrystalline cellulose pregelatinised maize starch quinoline yellow active: carbidopa monohydrate 27mg equivalent to carbidopa 25 mg levodopa 100mg excipient: magnesium stearate maize starch microcrystalline cellulose quinoline yellow starch - sinemet is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinemet frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of sinemet usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, sinemet permits more patients to obtain adequate relief of the symptoms of parkinson's disease. sinemet is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lansoprazole 15mg (lansoprazole (r,s racemic mixture));   - capsule - 15 mg - active: lansoprazole 15mg (lansoprazole (r,s racemic mixture))   excipient: gelatin   hypromellose macrogol 6000 mannitol meglumine methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc purified water   quinoline yellow   sodium laurilsulfate sugar spheres titanium dioxide     - healing and long-term management of reflux oesophagitis healing and maintenance therapy for patients with duodenal ulcer healing of benign gastric ulcer lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - spironolactone 100mg - tablet - 100 mg - active: spironolactone 100mg excipient: erythrosine lactose monohydrate magnesium stearate microcrystalline cellulose peppermint oil polysorbate 80 povidone purified talc quinoline yellow sodium starch glycolate starch sunset yellow fcf - essential hypertension; oedematous conditions including congestive heart failure, cirrhosis of the liver, (with or without ascites) and the nephrotic syndrome; idiopathic oedema; diagnosis and treatment of primary aldosteronism, as adjunctive therapy in malignant hypertension; in hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - spironolactone 25mg - tablet - 25 mg - active: spironolactone 25mg excipient: erythrosine lactose monohydrate magnesium stearate microcrystalline cellulose peppermint oil polysorbate 80 povidone purified talc quinoline yellow sodium starch glycolate starch sunset yellow fcf - essential hypertension; oedematous conditions including congestive heart failure, cirrhosis of the liver, (with or without ascites) and the nephrotic syndrome; idiopathic oedema; diagnosis and treatment of primary aldosteronism, as adjunctive therapy in malignant hypertension; in hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 100ug (plus a 3% manufacturing overage); levothyroxine sodium 100ug (plus a 9% manufacturing overage) - tablet - 100 mcg - active: levothyroxine sodium 100ug (plus a 3% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake active: levothyroxine sodium 100ug (plus a 9% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 300ug (plus a 9% manufacturing overage); levothyroxine sodium 300ug (plus a 2% manufacturing overage) - tablet - 300 mcg - active: levothyroxine sodium 300ug (plus a 9% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake active: levothyroxine sodium 300ug (plus a 2% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - levothyroxine sodium 88ug (plus a 3% manufacturing overage); levothyroxine sodium 88ug (plus a 9% manufacturing overage) - tablet - 88 mcg - active: levothyroxine sodium 88ug (plus a 3% manufacturing overage) excipient: acacia d&c olive lake blend lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose active: levothyroxine sodium 88ug (plus a 9% manufacturing overage) excipient: acacia d&c olive lake blend lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lymecycline 408mg equivalent to 300 mg tetracycline base - capsule - 300 mg - active: lymecycline 408mg equivalent to 300 mg tetracycline base excipient: erythrosine gelatin hydrated silica indigo carmine magnesium stearate quinoline yellow sulfur dioxide titanium dioxide - tetralysal is a broad spectrum antibiotic and is recommended for the treatment of all infections caused by tetracycline sensitive organisms and may be utilised in all conditions where tetracycline therapy is indicated. in common with other tetracyclines it is indicated in penicillin-sensitive patients for the treatment of staphylococcal infections. typical infections include: ear, nose and throat infections; acute and chronic bronchitis (including prophylaxis); infections of the gastrointestinal and urinary tracts; non-gonococcal urethritis of chlamydial origin; and other chlamydial infections such as trachoma; acne; rickettsial fevers; soft tissue infections.